Abstract
This article describes the functions and general responsibilities of the First Evaluation and Registration Division of the Pharmaceutical Affairs Bureau of the Ministry of Health and Welfare in Japan. It also discusses the Japanese perspective regarding regulatory concerns of acceptability of foreign clinical data.
Get full access to this article
View all access options for this article.